DR. JOSEPH D SPAHN, MD
Medical Practice at 16 Ave, Denver, CO
License number
Colorado 31045
Category
Medical Practice
Type
Pediatrics
License number
Colorado 31045
Category
Medical Practice
Type
Pediatric Allergy/Immunology
Address
Address
13123 E 16Th Ave, Denver, CO 80045
Phone
(720) 777-1234
Personal information
See more information about JOSEPH D SPAHN at radaris.comName
Address
Phone
6316 Xavier St, Arvada, CO 80003
459 Poplar Way, Denver, CO 80224
469 Poplar Way, Denver, CO 80224
8814 Utica St, Westminster, CO 80031
Professional information
See more information about JOSEPH D SPAHN at trustoria.com
Joseph Damian Spahn, Denver CO
Joseph Damian Spahn, Denver CO
Specialties:
Allergy & Immunology, Pediatrics, Pediatric Allergy & Immunology
Work:
Main Campus
1400 Jackson St, Denver, CO 80206
1400 Jackson St, Denver, CO 80206
Education:
University of Colorado (1986)
Methods Of Diagnosing Steroid-Resistant Inflammation Due To Type I Or Type Ii Nuclear Glucocorticoid Receptor Binding Abnormalities
Methods Of Diagnosing Steroid-Resistant Inflammation Due To Type I Or Type Ii Nuclear Glucocorticoid Receptor Binding Abnormalities
US Patent:
5567590, Oct 22, 1996
Filed:
Jan 6, 1994
Appl. No.:
8/178220
Inventors:
Donald Y. M. Leung - Englewood CO
Stanley J. Szefler - Aurora CO
Joseph D. Spahn - Denver CO
Stanley J. Szefler - Aurora CO
Joseph D. Spahn - Denver CO
Assignee:
National Jewish Center for Immunology and Respiratory - Denver CO
International Classification:
C07K 1472, G01N 3353, G01N 33567
US Classification:
435 72
Abstract:
Disclosed is a method for diagnosing inflammation in an animal which includes analyzing cells to assess glucocorticoid receptor binding affinity or glucocorticoid receptor number. A low binding affinity and high receptor number are each indicative of inflammation. Also disclosed is a method for treating inflammation in an animal, which inflammation causes glucocorticoid receptor alteration which includes suppressing the activity or expression of cytokines which, in the absence of suppression, alter glucocorticoid receptors. Also disclosed are methods for identifying Type II glucocorticoid receptor binding abnormality and for distinguishing Type I glucocorticoid receptor binding abnormalities from Type II. Further disclosed are treatments for steroid-resistant inflammatory disorders induced by IL-2 and IL-4 which are associated with glucocorticoid receptor binding abnormalities. The treatment includes administering an agent which is an IL-2 suppressor and/or an IL-4 suppressor.
Genetic Predictor Of Efficacy Of Anti-Asthmatic Agents For Improving Pulmonary Function
Genetic Predictor Of Efficacy Of Anti-Asthmatic Agents For Improving Pulmonary Function
US Patent:
2006006, Mar 30, 2006
Filed:
Jul 7, 2005
Appl. No.:
11/176026
Inventors:
Robert Lemanske - Madison WI, US
Christine Sorkness - Madison WI, US
Vernon Chinchilli - Elizabethtown PA, US
Wenlei Liu - Palmyra PA, US
Brenda Phillips - Elizabethtown PA, US
Robert Zeiger - San Diego CA, US
Gregory Heldt - , US
Fernando Martinez - Tucson AZ, US
Walter Klimecki - Vail AZ, US
Theresa Guilbert - Tucson AZ, US
Wayne Morgan - Tucson AZ, US
Stanley Szefler - Aurora CO, US
Gary Larsen - Littleton CO, US
Lynn Taussig - Greenwood Village CO, US
Joseph Spahn - Denver CO, US
Robert Strunk - St. Louis MO, US
Leonard Bacharier - Town & Country MO, US
Gordon Bloomberg - St. Louis MO, US
Christine Sorkness - Madison WI, US
Vernon Chinchilli - Elizabethtown PA, US
Wenlei Liu - Palmyra PA, US
Brenda Phillips - Elizabethtown PA, US
Robert Zeiger - San Diego CA, US
Gregory Heldt - , US
Fernando Martinez - Tucson AZ, US
Walter Klimecki - Vail AZ, US
Theresa Guilbert - Tucson AZ, US
Wayne Morgan - Tucson AZ, US
Stanley Szefler - Aurora CO, US
Gary Larsen - Littleton CO, US
Lynn Taussig - Greenwood Village CO, US
Joseph Spahn - Denver CO, US
Robert Strunk - St. Louis MO, US
Leonard Bacharier - Town & Country MO, US
Gordon Bloomberg - St. Louis MO, US
International Classification:
A61K 31/56, A61K 31/47
US Classification:
514171000, 514311000
Abstract:
The present invention relates to methods for determining and predicting the efficacy of therapeutics for the treatment of an individual with asthma based on that individual's β-adrenergic receptor. The invention finds particular applicability to the treatment of an individual with asthma with an inhaled corticosteroid or a leukotriene receptor antagonist who is homozygous for arginine at position 16 of the β-adrenergic receptor.